Skip to content

GLP-1 and incretin · compound · regulatory review 2026-10-09

Cagrilintide

Investigational long-acting amylin analogue.

The cited evidence and any approval concern the studied or labeled preparation. Oral, nasal, cosmetic and research-market versions do not inherit product approval or proven efficacy.

Editorial review 2026-10-12. source-curated; clinician review pending.

FDA product
not approved
Compounding
restricted
Research
investigational
Sport
unknown

What is Cagrilintide?

The amylin path is different from GLP-1, though combination trials with semaglutide exist. A research C-10 vial is not trial material. The mechanism language is receptor science. It is not a wellness claim.

In plain language

Cagrilintide is a long-acting amylin stand-in still in studies. FDA has not approved it. FDA says it cannot be used in compounding under federal law. Human obesity trials exist. They do not allow unsupervised use or research-market vials. Listed sizes here are 5 mg and 10 mg. Trial stays trial.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Human trial

Primary evidence or regulator source

706 adults without diabetes, overweight/obesity

Reported findings. In a 26-week phase 2 randomized trial of 706 adults with overweight or obesity, without diabetes, estimated average weight loss ranged from 6.0% to 10.8% across weekly subcutaneous cagrilintide study groups, versus 3.0% with placebo. These figures assume treatment adherence; doses increased over up to six weeks. These are study results, not dosing advice.

Nonresponse. The abstract does not report the proportion who failed to reach a weight-loss threshold. Treatment discontinuation is not a nonresponse rate.

Harms. Gastrointestinal events affected 41%–63% of cagrilintide participants versus 32% with placebo; administration-site reactions were also frequent. Across all groups, 10% permanently stopped treatment, including 4% because of adverse events.

Limits. No transfer to other routes/formulations/indications; clinician review pending. The primary figures use an analysis assuming adherence. The abstract reports similar reductions when nonadherence was included, without numerical detail. Participants and investigators knew which active treatment was assigned; active versus placebo was masked. These monotherapy findings do not establish combination, other-route or commercial-preparation outcomes.

Preparation: Cagrilintide monotherapy Route: subcutaneous

Read original source ↗

Editorial review 2026-10-12. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not approved. FDA identifies this investigational substance as unapproved.

Compounding

restricted. FDA states this substance cannot be used in compounding under federal law.

Research

investigational. Human obesity trials; investigational evidence is not product approval.

Sport

unknown. Not individually verified; consult the current sport rules. Absence of a listing is not permission.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified formulation-specific human estimate in this source set; no guessed value is supplied.

Listed sizes are 5 mg and 10 mg. Do not copy a combination-trial schedule onto a single research vial. Hold the carton.

U-100 math for listed Cagrilintide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
5 mg502516.7
10 mg1005033.3

Risks and mix-ups already on the record

  • Safety is incomplete; absence of reports does not establish safety.
  • Unknown or incomplete for research formulations; this is not a clearance for use.
  • Unknown or incomplete; do not infer compatibility with medications or other substances.

People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.

Sources

  1. Primary evidence or regulator source · checked 2026-10-09
  2. FDA unapproved GLP-1 safety statement · checked 2026-10-09
  3. ClinicalTrials.gov cagrilintide records · checked 2026-10-09

Questions people ask

Is cagrilintide approved if it has Phase 2 data?

Study evidence is not product approval. FDA records this substance as unapproved and restricted for compounding as of the catalog check date.

Does this page cover CagriSema?

This page does not treat CagriSema as a stack product. Combination trial names belong in a later compare or research card with their own citations.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.

Optional merchant comparison

Where to buy Cagrilintide

Compare the same identity, formulation and format. Blends, oral products and different variants stay separate. A lower price does not establish product quality or medical suitability.

We earn a commission when you buy through PepStar LLC partner links or codes RICHPEP and PEPBEAR. Merchant listings are separate from the evidence and do not establish product quality or medical suitability.

Other dated listings with incomplete quantity or equivalence verification (2)

Individual listing · equivalence unverified

Cagrilintide product listings. Prices exclude unverified shipping and tax.
Price / savingsProduct / quantityTerms / availabilityAction
Price unavailableProduct subtotal. Shipping and tax excluded where unverified.Cagrilintide 10mgAscensionFormulation not verified · format not verifiedQuantity not verified. No total mg or price per mg.Listed in stock

50% repeat-use program confirmed. Item eligibility, code and stacking unverified; no coupon included in this price.

Dates and offer terms

Price verified: not verified. Quantity verified: not verified.

Listing observed: Oct 9, 2026. Confirm availability with the seller.

Item terms verified: not verified. Eligibility: unknown. Stacking: unknown.

50% repeat-use coupon program confirmed Oct 9, 2026. Actual code, item exclusions and stacking need confirmation before checkout.

Shipping: not verified; seller charges excluded. Tax: not verified; excluded.

View product: Cagrilintide 10mg at Ascension (opens new tab)Exact merchant listingPartner customer link (opens new tab)Opens the partner referral page. Choose the exact product there; this is separate from the listing above.
Listing source

listing · Oct 9, 2026

Individual listing · equivalence unverified

Cagrilintide product listings. Prices exclude unverified shipping and tax.
Price / savingsProduct / quantityTerms / availabilityAction
Price unavailableProduct subtotal. Shipping and tax excluded where unverified.Cagrilintide — 5mg / PremiumLimitless Life NootropicsFormulation not verified · format not verifiedQuantity not verified. No total mg or price per mg.Listed in stock
RICHPEP

Coupon terms unverified. Item eligibility and stacking unverified; no coupon included in this price.

Dates and offer terms

Price verified: not verified. Quantity verified: not verified.

Listing observed: Oct 9, 2026. Confirm availability with the seller.

Item terms verified: not verified. Eligibility: unknown. Stacking: unknown.

Shipping: not verified; seller charges excluded. Tax: not verified; excluded.

View product: Cagrilintide — 5mg / Premium at Limitless Life Nootropics (opens new tab)Exact merchant listingPartner customer link (opens new tab)Opens the partner referral page. Choose the exact product there; this is separate from the listing above.
Listing source

listing · Oct 9, 2026